Sleep disorders stories

Aug 5, 2026

FDA approves Takeda's Orzeyful, first orexin agonist drug for narcolepsy type 1

The FDA has approved Takeda's Orzeyful (orexin agonist) for treating narcolepsy type 1 in adults, marking the first approval in a new class of sleep medicines that addresses the full range of narcolepsy symptoms. The approval is expected to reshape the treatment paradigm and launch a closely watched commercial drug race.

Aug 5, 20265 sources

Apr 21, 2026

Frequent Daytime Napping Linked to Early Signs of Health Decline in Older Adults

Frequent, long, or early-day naps in older adults are linked to higher mortality risk and may signal underlying conditions like cardiovascular disease, neurodegeneration, or sleep disorders, suggesting daytime sleep patterns could serve as an early warning sign of declining health.

Apr 21, 20264 sources

Top claims

▪In the Phase 3 FirstLight and RadiantLight clinical trials, Orzeyful demonstrated statistically significant improvements over placebo in excessive daytime sleepiness, cataplexy, and quality of life.
▪Patients treated with Orzeyful showed Epworth Sleepiness Scale score improvements of up to 9.8 points versus placebo, bringing patients close to the normal wakefulness range.
▪Jefferies analysts estimate that Orzeyful could cost between $142,000 and over $250,000 per patient annually, with peak net annual sales predicted to reach roughly $2 billion.

Subtopics

Drug Approval and Clinical Trials2 Sleep & circadian rhythm2 Age related cognitive decline1 Biomarkers & bloodwork testing1 Cardiovascular aging experts1 Cardiovascular diseases1 Drug development1 Lifestyle, Wellness and Nutrition1 Longevity & aging1 Neurodegeneration1 Pharma1 Preventive medicine1 Sleep optimization1

Related timelines